In short
This article discusses an innovative clinical trial investigating the use of Allogeneic Umbilical Cord Mesenchymal Cells-Derived Extracellular Vesicles (EXOB-001) in preventing bronchopulmonary dysplasia (BPD) in extremely preterm newborns. The study aims to assess the safety and efficacy of this novel treatment approach, which could potentially improve outcomes for premature infants at risk of developing lung complications.
At a glance
- Study Type
- Phase I single arm, dose escalating and Phase II double blind, randomized, placebo-controlled dose finding clinical trial
- Intervention
- Intratracheal administration of EXOB-001 (Allogeneic Umbilical Cord Mesenchymal Cells-Derived Extracellular Vesicles)
- Target Condition
- Bronchopulmonary Dysplasia (BPD) in extremely preterm newborns
- Primary Objectives
- Phase I: Assess acute and short-term safety of EXOB-001; Phase II: Assess efficacy in reducing BPD grade II-III at 36 weeks postmenstrual age
- Key Eligibility Criteria
- - 23-28 weeks gestational age at birth; - Birth weight 500-1500g; - Requiring mechanical ventilation
- Follow-up Duration
- Up to 2 years corrected age
- Key Outcomes
- - Safety and tolerability of EXOB-001; - BPD incidence and severity; - Lung development and function; - Neurodevelopmental outcomes; - Respiratory morbidity
What is EXOB-001?
EXOB-001 is a new medical treatment being studied for extremely preterm newborns. It's made from special particles called extracellular vesicles that come from umbilical cord mesenchymal cells. These cells are collected from donated umbilical cords, so the treatment is considered "allogeneic," which means it comes from a donor rather than the patient themselves.
The full name of this treatment is "Allogeneic Umbilical Cord Mesenchymal Cells-Derived Extracellular Vesicles," but it's easier to remember it as EXOB-001. It's also sometimes called by its sponsor product code, which is the same: EXOB-001.
What is Bronchopulmonary Dysplasia (BPD)?
Bronchopulmonary dysplasia (BPD) is a serious lung condition that affects some premature babies, especially those born extremely early (before 28 weeks of pregnancy). When babies are born this early, their lungs are not fully developed. They often need help breathing with machines and extra oxygen. While this support is necessary, it can sometimes damage their delicate lungs, leading to BPD.
Babies with BPD may have trouble breathing and need oxygen support for a long time. This can affect their growth and development, and may lead to long-term health problems.
How EXOB-001 Works
EXOB-001 is given to babies through their breathing tube directly into their lungs. This method is called intratracheal administration. The extracellular vesicles in EXOB-001 are tiny particles that can carry important signals and materials between cells. Scientists believe these vesicles might help reduce inflammation and promote healing in the lungs of premature babies, potentially preventing or reducing the severity of BPD.
Clinical Trial Overview
EXOB-001 is currently being studied in a clinical trial called EVENEW. This is a "first in human" trial, which means it's the first time this treatment is being tested in people. The trial has two main parts:
- Phase I: This part focuses on testing the safety of EXOB-001 and finding the right dose. Researchers will carefully monitor babies for any side effects.
- Phase II: This part will compare EXOB-001 to a placebo (a harmless substance with no active ingredients) to see if it helps prevent or reduce BPD.
Who Can Participate in the Trial?
The trial is looking for extremely premature babies who meet specific criteria. Some key points include:
- Babies must be between 23 and 28 weeks gestational age at birth
- They must weigh between 500g and 1500g at birth
- They need to be on a breathing machine with extra oxygen
- They must be between birth and 10 days old when starting the trial
There are also several reasons why a baby might not be able to participate, such as having certain heart defects, lung malformations, or infections.
Potential Benefits of EXOB-001
While it's important to remember that EXOB-001 is still being studied and its benefits are not yet proven, researchers hope it might:
- Reduce the number of babies who develop severe BPD
- Help babies need less time on breathing machines
- Improve lung development
- Reduce the risk of other complications related to prematurity
Safety Considerations
The main goal of the Phase I part of the trial is to check the safety of EXOB-001. Researchers will be watching closely for any side effects, especially in the first few hours and days after the treatment is given. They'll be looking at things like changes in heart rate, blood pressure, and oxygen levels.
Long-term Follow-up
The trial plans to follow the babies for up to 2 years after they would have been born if they hadn't been premature (called "corrected age"). During this time, researchers will check on the babies' overall health, especially their lung health. They'll also look at the babies' development using special questionnaires for parents.
This long-term follow-up is important to understand not just the immediate effects of EXOB-001, but also how it might impact children's health and development as they grow.